When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

And as of early November, there's one more big green flag suggesting that investors ... directly compete with the likes of Eli Lilly and Novo Nordisk, the big pharmas that currently split the ...

Zealand Pharma A/S briefly reclaimed its position as this year’s best performer in the Stoxx 600 Health Care Index on Friday, ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

The pharmaceutical company says data on 10 deaths and more than 100 hospitalizations comes from the FDA’s adverse event reporting database for semaglutide — the key ingredient in Ozempic and Wegovy, ...

MariTide, positioned as a monthly alternative to weekly injections offered by competitors Novo Nordisk NVO and Eli Lilly ...

The reactions to Donald's Trump's victory across the crypto, currency, and stock markets. Super Micro's woes, and the outlook for a company with no auditor, no annual report and, perhaps soon, no ...

Unfortunately, Big Government getting it wrong on food, nutrition, and health did not begin with COVID-19 or even the ...

New data from Novo Nordisk’s phase 3 trial of an oral ... survodutide 4.8 mg versus 4.3% of controls. There was one red flag in the data, however; namely, that around a quarter (24.6%) of ...

Like Novo Nordisk's already-approved GLP-1 agonist Wegovy ... only reduce weight but also curb appetite. There was one red flag in the phase 2 data, as around a quarter of patients taking the ...